Azetukalner (XEN1101)

Focal onset seizures

Manufacturer: Xenon Pharmaceuticals
Regulatory submission: NDA submitted September 2026
Launch: Not announced
Last updated: September 21, 2026

Section

Product information and disease description Product description

Product information

73 evidence topics · 20 sources

Generic, brand name and therapeutic class of product4 evidence topics · 4 sources
Dosage forms and strengths4 evidence topics · 4 sources
Average sales price and wholesale acquisition cost4 evidence topics · 4 sources
American hospital formulary service (AHFS), or other drug classification1 evidence topic · 2 sources
Indication3 evidence topics · 3 sources
Pharmacology20 evidence topics · 12 sources
Contraindications/Warnings/Precautions/Adverse effects7 evidence topics · 5 sources
Special populations3 evidence topics · 2 sources
Drug/Drug, drug/disease interactions7 evidence topics · 5 sources
Dosing and administration6 evidence topics · 5 sources
Access and distribution2 evidence topics · 1 source
Co-prescribed/Concomitant therapies5 evidence topics · 5 sources
Product comparison7 evidence topics · 5 sources

Effect of Azetukalner on quality measures

No evidence found.